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Abstract
Patients with metastasised prostate cancer survive longer with anti-androgen therapy but eventually all 
progress into the androgen-ablation refractory (AAR) stage and die. There are only few effective strategies to 
treat patients with AAR cancers and they include even more effective androgen blockade by for example 
glucocorticoids or ketoconazole. Some of the tumours differentiate into neuroendocrine tumours and become 
completely independent of androgen stimulation. It is believed that these tumours over-express somatostatin 
receptors which may be a new target for the anti-tumour treatment. In this article we present a patient 
with advanced AAR prostate cancer and intractable retching and vomiting. As the last resort, he was treated 
with octreotide SC which resulted rapid amelioration of the symptoms and in significantly decreased PSA 
which could be translated into longer survival. In this article we review rationale for the use of somatostatin 
analogues in the treatment of patients with hormone-refractory prostate cancer.
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Introduction
Despite annual decrease in incidence, prostate 
cancer is still one of the main causes of cancer re-
lated death in the western world [1, 2]. Screening 
and early detection managed to reduce mortality 
slightly down, but in many cases lead to overtreat-
ment and loss of quality of life [3, 4]. Disease limited 
to the prostate has a good chance of cure with 
resection and radiotherapy, but metastatic disease 
becomes uncontrollable with an inevitable outcome. 
Androgen deprivation therapy is used as standard 
to induce apoptosis of malignant cells [1]. How-
ever, eventually the tumour cells become hormone 
refractory, and progress to hormone-refractory or 
castration-resistant prostate cancer [5, 6]. Most 
often this stage becomes apparent when there 
is a rise in prostate specific antigen (PSA) levels de-
spite adequate androgen deprivation [7, 8].  Once 
this stage has been reached there are few evidence 
based medical therapies available to the patients. 
However, some of them are in development, and 
appear to be promising [9]. Inhibiting the systemic 
biosynthesis of androgens with ketoconazole in 
castration resistant prostate cancer by targeting 
CYP17 is one of the new therapeutic approach since 
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this enzyme catalyses two key steroid reactions in-
volving 17alpha-hydroxylase and C(17,20)-lyase in 
the androgen biosynthesis pathway [10]. Another 
approach is to administer glucocorticoids which 
has some clinical advantages [11]. It is intriguing 
that some of the prostate cancers may completely 
bypass the androgen pathway and may differenti-
ate to neuroendocrine cancers which over-express, 
among others somatostatin (SST) receptors [6]. In 
this article we present a patient with advanced pros-
tate cancer and intractable retching and vomiting 
who responded to administration of octreotide and 
lanreotide. We shall discuss our current knowledge 
and perspectives of the use of somatostatin ana-
logues (SST-As) both in palliation of the symptom 
as inhibition of the tumour growth.
Case report
An 80-year-old man was diagnosed with meta-
static prostatic carcinoma in 2000, previously treated 
with androgen deprivation and radiotherapy for 
his metastasis, was admitted to the hospice in Oc-
tober 2009. Although living at home he was known 
to the hospice because of problems with sweat-
ing. He did have bone pain prior to admission. On 
admission he was suffering from significant pain 
despite Tramadol 100 mg tds, had minimal intake 
and a marked degree of dysphagia. He was also 
retching and vomiting on a regular basis. No nausea 
except seconds before vomiting. His PSA had risen 
from 31 in April 2009 to 500 ng/mL. His pain control 
was improved with a buprenorphine patch 20 μg/h, 
as well as 5 mg oral morphine PRN of which he used 
1–2 doses per day. After trying multiple avenues to 
control his retching and vomiting with glucocor-
ticosteroids, metoclopramide, levomepromazine, 
discontinuation of some medications, zinc sulphate 
supplements, and acupuncture, he was started on 
SC octreotide 500 μg/24 hours while continuing with 
low dose dexamethazone, 2 mg od. His vomiting 
stopped almost immediately and he was able to eat 
more and became mobile again. He was discharged 
to home and seen regularly on an outpatient basis. 
Just before discharge he was swapped to a lanreotide 
IM injection (Somatuline®depot, 60 mg once per 
month) and began a gradual improvement with an 
increase in appetite, weight gain and better pain 
control. In February 2010 his PSA had come down to 
360 ng/mL. However, by April he was deteriorating 
again and his PSA had risen again, so the lanreotide 
was discontinued. By May his PSA was 950 ng/mL, 
and he was suffering again with loss of mobility and 
increasing pain. In August he was admitted to the 
hospice with pain and recurrence of retching and 
vomiting. He was, again started on SC octreotide 
500 μg/24 hours which this time resulted in improve-
ment of retching and vomiting after approximately 
three weeks. Again, he was swapped to lanreotide 
and could be discharged in October 2010 to home. 
He was readmitted in November 2010 for terminal 
care most probably with the fracture of the lumbar 
vertebrae. His PSA was than 5600 ng/mL. His retching 
and vomiting was controlled until death.
Discussion
This case obviously brings up the question of 
what role somatostatin analogues (SM-As) such 
as octreotide and lanreotide have to play in the 
management of metastasized prostate cancer.  
Rationale
Somatostatin has a wide range of effects within 
the body, the main one of which is suppression of 
growth hormone secretion [12]. Apart from this, 
its receptors are present in most of the body’s tis-
sues to some extent, and is said to serve as the 
body’s ‘endocrine off switch.’ The possibility of 
somatostatin analogues being used in the treat-
ment of solid tumours has been known for about 20 
years [12]. Although more is known now; it would 
seem that we are not using this therapy to its full 
advantage. Somatostatin also had been thought to 
be effective in pain control, as many peripheral nerve 
endings express SST receptors [13, 14]. 
Some hormone-refractory prostate cancers dif-
ferentiate to neuroendocrine tumours [6]. Neuroen-
docrine cells are present in 40 to 100 percent of 
patients with hormone-refractory prostate cancer, 
depending on the study [6]. These neuroendocrine 
cells over-express express somatostatin recep-
tors available as a treatment target [15]. 
Background
Somatostatin is known to bind to 5 different 
hormone receptors, named sst1-5. Additionally there 
are two variants of sst2, known as sst2A and sst2B. Ap-
parently, sst2A seems to be the more active form in 
humans. Somatostatin itself is not clinically useful 
as it has a very short half life, but the wide range of 
effects this hormone has highlights its potential for 
use in a wide range of clinical conditions [15]. The 
three SST-As currently licensed for use are octreotide, 
lanreotide and vapreotide. These bind with high affin-
ity to sst2 and sst5, with limited affinity for sst3 [15]. 
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Apart from having a longer half life than the endog-
enous hormone, they have very mild toxicity profiles, 
with the main side effects being GI disturbances and 
altered glucose metabolism [16]. 
Pre-clinical evidence
One study looking into the regulation of prostate 
cancer cells by somatostatin activation showed that 
in specific androgen dependant prostate cancer cell 
lines all the sst-s are expressed but sst4 [17]. Using 
SST-As with various receptor affinities it was found 
that all the analogues used inhibited cell proli-
feration but that sst1 agonists and the bi-specific 
compounds which were preferential agonists for 
sst2/sst5 (BIM-23244 and lanreotide) showed the 
greatest inhibition [17]. Although sst1,2,4 and 5 all 
lead to a decrease in proliferation, sst3 can have 
a pro-apoptotic effect via induction of the tumour 
suppressor protein p53 [18], as can sst2 via a diffe-
rent pathway [19]. 
Apart from inhibiting cell proliferation BIM-23244 
and lanreotide also affect the insulin like growth 
factor (IGF) system by inhibiting autocrine and para-
crine hormones such as epidermal growth factor 
(EGF), interleukin-6 (IL-6) and tumour growth fac-
tors (TGFs), IGF I and II, and by altering the secretory 
profile of the IGF system [15, 17]. This is of clinical 
significance as these are known as ‘survival fac-
tors’ whose presence encourages the survival and 
growth of malignant cells. These are particularly 
important in prostate cancer as micrometastatic loci 
are encouraged by such survival factors to develop 
into macrometastasis [15]. According to this study 
somatostatin acts to decrease the amount of IGF-I by 
decreasing production in the tumour microenviron-
ment, by inhibiting growth factors (GFs) release 
from the pituitary, and by decreasing serum insulin 
levels. There is also evidence to suggest that tumour 
size may be regulated by a number of effects on the 
process of neoangiogenesis. 
Furthermore, there is some evidence to suggest 
that SST activation may re-establish contact inhibi-
tion prohibiting tumour growth and also reduce 
adhesion of some cancer cells to the endothelial 
basement membrane making metastatic develop-
ment less likely [20]. 
Interestingly it has also been shown that many 
patients treated with SST-As will eventually become 
refractory to treatment due to tachyphylaxis [15]. 
There are thought to be a number of mechanisms in-
volved in this process including down regulation of 
some sst receptors (ssts in particular) after exposure 
to SST-As [21], selection of SST-negative tumour 
cell clones, and SST gene mutations, although the 
evidence for these processes are relatively weak [22]. 
Clinical evidence
The idea  that prostate cancers may differen-
tiate into neuroendocrine tumours that produce 
paracrine factors with proliferative properties lies at 
the basis of this concept. Potential mechanisms of 
antitumor action include suppression of circulating 
levels of trophic hormones and growth factors. Vari-
ous tumours have high concentrations of sst recep-
tors which may be used for their clinical detection 
with Indium-111 -DOTA-lanreotide [23]. 
Probably the best investigated are the combina-
tions of SST-As with some other hormonal measures. 
Dexamethasone plus LHRH analogue together with 
lanreotide produces objective clinical responses in 
10 out of 11 patients with AAR prostate cancers. 
Besides substantial decrease of the PSA marker, pa-
tients also reported improvement of bone pain for 
a median of 13 months and improvement of perform-
ance status [24]. In a systematic analysis of 42 tri-
als with 267 AAR prostate cancer patients, SST-As were 
found to be effective, particularly when combined 
with estrogens or corticosteroids. The side effects are 
mild and related to the gastrointestinal tract [25]. 
Palliative care perspective
This patient described by us suffered of intrac-
table retching and vomiting which responded to 
SST-As, first octreotide and later lanreotide. This re-
sponse was maintained in time. When the disease 
progressed under lanreotide and this drug was dis-
continued, retching and vomiting reappeared within 
months, but was again amenable to the treatment, 
even when the PSA remained unaffected. Prior to 
the treatment with octreotide, in November 2009, 
the patient was informed about poor prognosis and 
nearing end as his condition deteriorated daily. Effect 
of octreotide was surprising and certainly affected 
patients’ survival and quality of life. It is unclear 
whether dexamethazone, continuously administered 
all this time played here any role or not. However, 
seen the results of the trials [24] it is very well prob-
able that dexamethazone contributed to this effect. 
It certainly that dexamethazone alone was unable 
to control retching and vomiting. Interesting is the 
report that dexamethasone, LHRH analogues and 
SST-A were able to decrease the bone pain [24]. 
Our patient, after he started with SST-As was able 
for many month maintain good analgesia with only 
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buprenorphine patch 20 μg/h and practically no 
other pain controlling measures. 
Conclusion
SST-A are expensive and not readily available to all 
palliative care specialists. We think that SST-As may 
be useful in advanced prostate cancer, not only for 
control of the symptoms, but also to improve survival 
and quality of life until death.  
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